2016 International Congress

Thursday, June 23, 2016

12:00pm-1:30pm

Combined pallidal and thalamic stimulation for multifocal primary dystonia with prominent writers’ cramp

A. Wloch, M. Abdallat, G. Lütjens, C. Schrader, J.K. Krauss (Hannover, Germany)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Combined stimulation of STN and SNr for resistant freezing of gait in Parkinson’s disease (STN+SNr) – A multicenter randomized controlled trial

D. Weiss, G. Naros, C. Meisner, R. Krüger, A. Gharabaghi (Tübingen, Germany)

Clinical trials and therapy in movement disorders  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Comparing quality of PD care in a comprehensive clinic to specialist care

S.A. Factor, L.P. Prizer, F.C. Goldstein, L.M. Trotti, A. Hermida, C. Vaughan (Atlanta, GA, USA)

Other  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease

C. Mahapatra, R. Manchanda (Mumbai, India)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Conjugal Parkinson´s disease – Real or chance?

B. Balint, R. Erro, F. Brugger, A. Batla, E. Antelmi, C. Ganos, K.P. Bhatia (London, United Kingdom)

Other  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa

R. Shaltiel-Karyo, E. Zawoznik, I. Weinstock, M. Nemas, Y. Caraco, P.A. LeWitt, S. Oren, O. Yacoby-Zeevi (Rehovot, Israel)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Contributions of sensorial feedback to gait in Parkinson’s disease

F.A. Barbieri, L.T.B. Gobbi, P.C.R. Santos, R. Vitório, L. Simieli, D. Orcioli-Silva, M.B. Pestana, C.M. Fiorelli, Q. Almeida (Bauru, Brazil)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice

S.J. LoRusso, B. Ouyang, B.R. Barton (Chicago, IL, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns

J. Morgan, M. Stacy, R. Rubens, S. Khanna, S. Gupta (Augusta, GA, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Copper chelation efficacy of alginate/chitosan based D-penicillamine nanoparticles in rat model of non-Wilsonian brain copper toxicosis

A. Pal, B.R. Thapa, R.K. Vasishta, R. Prasad (Chandigarh, India)

Parkinson's Disease: Clinical Trials II and Non-PD Clinical Trials